Thursday 7 May, 2026
Introduction: Sub‑Saharan Africa (SSA) faces an outsized burden of infectious diseases but continues to be underrepresented in pharmacokinetic (PK) studies….
Read morePoster: Clinical Applications
Population Pharmacokinetics and Safety Assessment of Rifapentine in Chinese Children to Inform Dosing Recommendations for Latent Tuberculosis Infection
Thursday 16 October, 2025
Introduction Current treatment of latent tuberculosis infection (LTBI) include combined rifapentine (RFT) and isoniazid daily treatment for one month (1HP)…
Read moreUsing Bayesian Modelling to Evaluate the Effect of a Neonatal Vancomycin Loading Dose on Therapeutic Target Attainment in a Low-Middle Income Country
Thursday 16 October, 2025
Introduction: Vancomycin, a glycopeptide antibiotic, has served as a cornerstone in treating hospital-acquired Gram-positive infections for over five decades. Recommended for…
Read morePopulation pharmacokinetic and pharmacodynamic analysis of granulocyte colony-stimulating factor (G-CSF) to optimize dose and timing for harvesting CD34+ cells
Thursday 16 October, 2025
Objectives: Filgrastim is a well-known granulocyte colony-stimulating factor (G-CSF), a cytokine for the maturation and mobilization of bone marrow neutrophils….
Read moreUnderdosing imipenem in patients with renal insufficiency: global clinical data-driven pharmacokinetic/pharmacodynamic study
Thursday 16 October, 2025
Objectives: Currently, population pharmacokinetic (popPK) models for imipenem in critically ill patients are available. However, they lack a good representation of…
Read moreA model-informed framework for prioritizing pharmacogenomic drug-gene interactions in an Asian context for chemotherapy
Thursday 16 October, 2025
Objectives: Despite making up more than 60% of the world’s population, Asian genomes are under-characterized. A large-scale whole genome sequencing…
Read moreTowards MIPD of Linezolid: External Evaluation of Population Pharmacokinetic Models
Thursday 16 October, 2025
Objectives: Overdosing of linezolid increases the risk of adverse events such as thrombocytopenia, lactic acidosis, or neuropathy, while underdosing may…
Read moreModel-informed dose optimization of mycophenolic acid in pediatric renal transplant patients
Thursday 16 October, 2025
Introduction: Mycophenolic acid (MPA), the active compound of the prodrug mycophenolate mofetil (MMF), is a pharmacotherapeutic cornerstone to prevent allograft…
Read morePopulation pharmacokinetic modelling of oral ruxolitinib: a real-world prospective observational study
Thursday 16 October, 2025
Objectives: Ruxolitinib is a small molecule targeting JAK1 and JAK2 proteins and used orally for the treatment of myeloproliferative disorders, such…
Read moreInvestigating Alternative Daily Dose Regimens for Bedaquiline in Treatment of Multidrug-Resistant Tuberculosis using an Interactive Shiny Application
Thursday 16 October, 2025
Objectives: Tuberculosis (TB) remains a major global health concern, especially multidrug-resistant (MDR) TB [1]. Bedaquiline (BDQ), is an effective drug for…
Read more